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The ‘Other Diseases’ of the
Millennium Development Goals:
rhetoric and reality of free drug
distribution to cure the poor’s
parasites
TIM ALLEN & MELISSA PARKER
ABSTRACT The sixth MDG aims ‘to combat HIV/AIDS, TB, malaria and other
diseases’. The residual category of ‘other diseases’ has become the focus of
intense interest, partly because it has provided an opportunity to increase
resources for the control of the mostly parasitic ‘neglected tropical diseases’
(NTDs). Intense lobbying has secured large amounts of funding from donors, as
well as generous donations of medicines from the major drug companies. A
massive programme is now underway to treat the parasites of the poor in Africa
via integrated vertical interventions of mass drug administration in endemic
areas. The approach has been hailed as remarkably eﬀective, with claims that
there is now a real prospect of complete control and, for some NTDs, even
elimination. However, a closer look at evaluation and research data reveals that
much less is known about what is being achieved than is suggested. Competition
between implementing organisations is leading to potentially counterproductive
exaggerations about treatment coverage. Detailed local-level research in
Uganda and Tanzania shows that actual rates of drug take-up among target
populations are often lower than is necessary to eﬀectively control the diseases,
and that methods of drug distribution may even lead to active resistance to
treatment. If current trends are not corrected, declining rates of NTD infection
will not be sustained. Much more rigorous and eﬀective monitoring is essential.
The sixth Millennium Development Goal (MDG) refers to a vague, residual
category. It aims ‘to combat HIV/AIDS, TB, malaria and other diseases’.
‘Other diseases’ is a label that quickly became the focus of intense lobbying,
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because capturing it would almost certainly guarantee a huge surge of
funding. By the mid 2000s a group of determined and passionate activists had
clearly won the day. They had shrewdly pooled their resources and networks
to claim that ‘one of the most convincing ways to make poverty history’ was
to control a group of infections referred to as the neglected tropical diseases
or ‘NTDs’.1 In 2005 the UN Millennium Project published a set of ‘Quick
Win’ interventions that were devised to deliver rapid results in attaining the
MDGs; an aspect of NTD control was highlighted as one of the most important
low-hanging fruits.
Campaigners have tended to use the NTD acronym as though it
encapsulates a clearly deﬁned and homogenous problem. It actually refers
to a diverse range of aﬄictions, mostly parasitic, which have historically been
endemic in large parts of the world. So successful has the NTD-control
movement been that we now have remarkable claims being taken seriously.
Sachs and Sachs, for example, tell us that ‘Controlling the NTDs is nothing
less than healing the world’,2 while Hotez and Thompson have published a
paper called ‘Waging peace through neglected tropical diseases: a US foreign
policy for the bottom billion’ in a respected medical journal.3
More soberly Hotez has explained that the NTDs are among the most
common infections of the poor. He estimates that one in four of the world’s
poorest people are infected with soil-transmitted helminths; one in 10 with
schistosomiasis; one in 20 with lymphatic ﬁlariasis and trachoma; and one in
50 with onchocerciasis. In total, he suggests, 1.1 billion of the world’s 2.7
billion people living on less that US$2 per day are infected with one or more
NTDs, and when the global disease burden of the most prevalent NTDs is
combined, the disability they cause rivals that of any of the big three.4 He and
his research colleagues have elaborated this latter point in studies comparing
the total number of disability-adjusted life years (DALYs), that have been lost
from either premature death or disability from NTDs as opposed to HIV/AIDS,
malaria and TB. By their calculations, NTDs collectively account for more lost
DALYs than either malaria or TB.5
The argument that developing integrated NTD control programmes is a
cost-eﬀective way forward was found to be particularly compelling. A key
paper, published in 2005, was co-authored by three of the most prominent
long-term advocates of mass drug administration: David Molyneux of the
Liverpool School of Tropical Medicine, Peter Hotez of the Sabin Vaccine
Institute in Washington (who has already been mentioned above) and Alan
Fenwick of London’s Imperial College.6 The paper argued that it is possible
for public–private partnerships to develop integrated control programmes for
seven major NTDs in Africa with only four drugs (albendazole, ivermectin,
praziquantel and azithromycin) at an estimated cost of $0.40 per person per
year. It went on to suggest that if $200 million could be spent each year for
ﬁve years, it would be possible to treat 500 million individuals. This, in turn,
would contribute to current strategies to alleviate poverty among the poorest
and most marginal people in the world. By way of contrast, it was also
pointed out that it costs $200 each year to treat one person with HIV/AIDS in
Africa; a further $200 to treat an individual with TB; and $7–$10 to treat each
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bout of malaria. The case to support these ‘rapid impact interventions’ was
stronger still, it was argued, considering the fact that there are millions of
people in Africa who are infected with a variety of parasitic infections, but
who do not suﬀer from HIV, TB or malaria.
In sum, those promoting NTD control argued that it represents one of the
most eﬃcient and cost-eﬀective means of achieving the MDGs in the areas of
child and maternal health, infectious diseases and poverty reduction. It could
also be a means of building global partnerships, and ‘a step forward in achi-
eving international human rights’.7 The ﬁrst WHO global report on
NTDs, published in 2010, reiterates these points. In the foreword the Director
General claims that NTDs ‘weaken impoverished populations, frustrate the
achievement of the health-relatedMillenniumDevelopment Goals and impede
global development outcomes . . . The logic has changed: instead of waiting for
these diseases to gradually disappear as countries develop and living conditions
improve, a deliberate eﬀort to make them disappear is now viewed as a route to
poverty alleviation that can itself spur socioeconomic development’.8
In many ways this has been a remarkable and positive change in thinking
about global public health. Thirty years ago there was very little funding or
support for the control of tropical parasitic infections other than malaria.
Indeed, there was not even much interest in the medical profession outside a
small coterie of specialists. It must come as something of a surprise to such
people that the World Health Organisation (WHO) now claims that treatment
of these diseases has always been one of its main priorities.
NTDs mostly aﬀect politically marginal populations in parts of the world
that are of little strategic or commercial interest to rich countries. Although
there have been important exceptions, in general, when attempted at all,
disease control has concentrated on more economically signiﬁcant places,
such as the Gezira/Managil irrigation region of Sudan. Some veterans of
combating NTDs, like Alan Fenwick, were involved in those programmes
and, whatever their status in the countries concerned, they may well have felt
like voices in the wilderness when they attempted to highlight the importance
of what they were doing on the global stage.9 Not now.
A 2009 report to an All-Party Parliamentary Group in the UK posed the
question: ‘The Neglected Tropical Diseases: a challenge we could rise to—
will we?’. The consensus, it seems, was by then already a resounding ‘yes’.
Since 2004 the Gates Foundation has allocated more than $46 million to NTD
control, but this has been dwarfed by the amounts allocated from the US aid
programme. US Agency for International Development (USAID) funding will
reach $350 million by 2013. The UK’s aid programme has also been caught
up in the enthusiasm, allocating £50 million by 2010. Compared with what
has been available in the past, these are extraordinary amounts of money,
and substantial further resources are on their way. At a meeting on NTDs in
Geneva on 14 October 2010 huge commitments were pledged by donors,
including massive quantities of drugs. GlaxoSmithKline, for example, is now
committed to donating a billion albendozole tablets per year to treat school-
aged children in Africa. Other drug companies, including Merck, Eisai,
Sanoﬁ-Aventis and Johnson&Johnson, have been almost as generous.
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So what exactly are these formerly ignored infections that have become the
not-so-neglected tropical diseases? Can they really be so readily controlled,
and what has been achieved so far? Our answer to the latter two questions is
that, perhaps not surprisingly, things are very much more complicated than is
claimed.
Controlling the NTDs
The ﬁve most common neglected tropical diseases and disease groups are:
lymphatic ﬁlariasis (otherwise known as elephantiasis), onchocerciasis (river
blindness), soil-transmitted helminths (intestinal parasitic worms such as
hookworm, ascaris and trichuris), schistosomiasis (bilharzia) and trachoma.
Other infectious diseases that are increasingly referred to as NTDs, no doubt
in part to jump on the bandwagon and secure resources for treatment,
include: African trypanosomiasis; chagas disease; dengue fever; leishmania-
sis, leprosy; cysticercosis; dracunculiasis (guinea-worm disease); echinococ-
cosis and foodborne trematode infections. These are all debilitating aﬄictions
and, in some instances, can prove fatal. Those who are also infected with HIV/
AIDS and/or TB and malaria are more likely to suﬀer the severe consequences
of one or more of these infections more quickly.
It is important to note, however, that the ﬁgures cited above about the
speciﬁc number of people aﬀected by diﬀerent NTDs and the data used in
calculating DALYs can be little more than ‘guesstimates’. Robust demo-
graphic and epidemiological data are only now beginning to be collected
systematically and still remain surprisingly sparse—a point we discuss below.
Nevertheless, it is irrefutable that a large proportion of the world’s most
deprived and marginalised people are infected with one or more NTD.
According to the ﬁrst WHO global report on NTDs, which collates evidence
from multiple sources, NTDs are endemic in 149 countries and territories,
with 30 of these being endemic for six or more NTDs. As the report
emphasises, these aﬄictions are associated with ‘substandard housing, lack of
access to safe water and sanitation, ﬁlthy environments, and abundant insects
and other vectors’.10 Even though it is not only the poor who catch them, it is
the poor who are more likely to be exposed to them. The poor have also had
little prospect of securing curative therapy, and in places where symptoms are
unchecked, the sight of numerous individuals suﬀering the consequences is
not something easily forgotten. There are very good reasons why long-term
protagonists like Molyneux, Hotez and Fenwick have remained so
committed to NTD control, and why people like Narcis Kabaterine, the
head of vector control at the Ministry of Health in Uganda—recently
hailed as the ‘Unsung Hero of Neglected Tropical Diseases’11—have
dedicated their professional lives to the cause with such enthusiasm.
In the context of growing interest and concern about these diseases, linked
to the possibilities of substantial funding under the auspices of the MDGs, a
new approach has been initiated, dwarﬁng previous eﬀorts to control
parasitic infections among impoverished populations. In its 2010 report on
NTDs, the WHO claims to have pioneered this paradigm shift in 2003. It
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asserts that the process was led by the former Director General and ‘involved
an important strategic change, from a traditional approach centred on
diseases to one responding to the health needs of marginalized commu-
nities’.12 This is a very odd way of accounting for what happened—one that
seems to ignore the history of global primary health care policy dating back
to the 1970s, in which WHO itself has played an important role.
Also, far from being any sort of grassroots initiative, what was actually
being promoted was a reorientation of vertical biomedical interventions
towards parasitic and other diseases for which there were potentially cheap,
safe and eﬀective cures. There was plenty of talk about comprehensive
solutions to improve the overall well-being of target populations but the
priority was clear. It was to undertake mass drug administration on a vast
scale. One aspect of the enthusiastic response to the approach was that, while
medical professionals were struggling to ﬁnd a viable clinical response to the
HIV/AIDS pandemic, here was a rapidly evolving and increasingly well
resourced strategic plan to combat dreadful sicknesses by supporting or
adapting existing medical systems and using readily available treatments.
In 2008 Molyneux, Hotez and Fenwick joined forces to throw the cat
among the pigeons with a paper in an open access medical journal. They called
for a new Global Fund to ﬁght NTDs, and argued that ‘there are 740 million
Africans who are not infected with HIV/AIDS; they deserve a slice of the
available interventions’.13 One of their co-authors was Lorenzo Savioli, of the
WHO, and the paper proposed that the new fund could be overseen by a board
utilising the WHO’s technical resources. However, the proposal was also a
potential threat to entrenched interests, and was by no means popular with all
staﬀ within the WHO. The institution had been largely sidelined by the setting
up of the Global Fund for HIV/AIDS, Malaria and TB, and there were concerns
about yet another big competitor. It may be for this reason that the WHO has
now attempted to assert—or reassert—the initiative with its 2010 NTD report.
A sense of the stakes involved can be gleaned from the wording of a ﬁve-year
WHO strategic plan for NTD control, dated August 2010, but circulated for
some time internally. A highlighted component of the plan is ‘strengthening
partnerships for NTD control at all levels and repositioning WHO as the
preferred partner.’14 In short, there is much more going on at the moment
than the straightforward presentation of evidence about NTD control.
Leaving aside overblown assertions about the ways in which NTD control
can resolve the world’s problems, as well as rhetoric about mass drug
administration going hand in hand with a broad range of poverty alleviation
measures, the strategy that is really being promoted by the WHO, its partners
and competitors is the massive roll out of drugs to people living in areas
where NTDs are endemic. The strategy is based on three key ideas. First,
signiﬁcant reductions in overall child and adult mortality and morbidity can
be achieved in poor countries, if relatively small proportions of public health
ﬁnance directed towards the control of HIV/AIDS, TB and malaria are
redirected towards the integrated control of certain parasitic infections.
Second, there are a number of drugs with a proven track record of success
which can be cheaply manufactured and easily administered to populations
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aﬀected by these NTDs. Third, it is more economical to administer the drugs
as one integrated, top-down, biomedical intervention, rather than through
multiple vertical structures running side-by-side. The main focus is sub-
Saharan Africa, where the targeted NTDs are known to be widespread and the
population most impoverished.
Against this background, several countries—including those in which we
have been researching, namely Uganda and Tanzania—are developing
national programmes for NTD control that scale up and aim to integrate
vertical treatment procedures. Drugs for selected diseases or groups of
diseases—notably schistosomiasis, onchocerciasis, lymphatic ﬁlariasis, soil-
transmitted helminths and trachoma—have been provided to ministries of
health. These programmes attempt to treat school-age children and adults
living in endemic areas, free of charge, on a regular basis. In accordance with
the World Health Assembly’s Global Targets, an endeavour is made to treat
high percentages of the population en masse, without ﬁrst testing individuals
to see if they are infected. For example, 75 per cent of at-risk populations are
supposed to be treated for schistosomiasis, soil-transmitted helminths and for
lymphatic ﬁlariasis. This is considered ethical, because the drugs are deemed
safe, apart from possible short-term side-eﬀects, and it is much less expensive
to provide drugs to everyone in endemic locations than to set up and sustain
diagnostic facilities.
The donated drugs are distributed from the headquarters of ministries of
health to staﬀ employed at a district level. These staﬀ then take responsibility
for mobilising and training school teachers and drug distributors at village
level who, in turn, are given responsibility for handing out drugs to all
children and adults living in areas where the diseases are endemic. In many
locations it is expected that populations will be infected with a combination
of NTDs. In these places multiple treatments are given at the same time, or
staggered through the year if the treatment protocols require it (such as when
there may be possible health risks in taking particular drug combinations).
To give an idea of the scale of these operations, in Uganda enough
albendazole and praziquantel tablets have been provided to treat some 0.4
million, 1.2 million, three million, 1.5 million and 1.8 million people for
schistosomiasis and soil-transmitted helminthiases in 2003, 2004, 2005, 2006
and 2007, respectively.15 Since 2007 there has been further expansion, as US
funding has come on stream. According to USAID’s implementing agency, RTI
International, in the third year of their support for programme implementa-
tion 27 656 133 treatments were supposedly administered to 13 687 841
people potentially infected with targeted NTDs in 72 districts.16
Given the large quantity of resources being provided for these programmes
and the needs of those involved in running them to sustain support by
producing results, it is perhaps predictable that assessments of what might be
achieved and what has been achieved tend to be very positive.17 The 2010
WHO report on NTDs adopts a similar tone. Towards the start the report
notes there are ‘challenges that will have to be faced if the current
achievements in NTD prevention and control are to be sustained and
extended’,18 but there is scant mention of those challenges in the pages that
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follow. It is claimed that 670 million people had been reached with preventive
chemotherapy by the end of 2008, and that for some diseases there is a
prospect of elimination by 2020. As the current Director-General of WHO
states in her foreword, ‘the overall message is overwhelmingly positive’.
However, there is a growing body of research which suggests that the
current approach to distributing drugs for NTDs is facing serious problems.
This is not a homogeneous critique, and many of those who have raised
concerns are among those who have been most committed to control of
Africa’s parasitic diseases over the long term. For example, the hazards of
relying upon unpaid volunteers to distribute tablets at the village level has
been raised by several authors,19 while others draw attention to the point that
current endeavours to ‘integrate’ vertical control programmes may lead to
the development of a parallel health-delivery system, with potentially serious
consequences for ministries of health.20 A related concern is raised by
Utzinger et al, who question the sustainability of control programmes that
rely so heavily upon preventive chemotherapy.21 Parker et al draw attention
to a diﬀerent set of issues by suggesting that it is mistaken for policy makers
and public health practitioners to assume that populations receiving drugs,
free of charge, will necessarily understand or agree with the rationale for
mass treatment. Instead, free treatment may be actively resisted.22 Finally, a
number of authors have highlighted limits in knowledge surrounding the
safety and eﬃcacy of combining drugs for some NTDs, and the consequences
of repeated treatments over many years.23
There is no space here to discuss all these points in detail but, in the light of
claims made in the ﬁrst WHO global report on NTDs, we draw on our research
in Uganda and Tanzania to comment on some of them. On page 10 of the
report, Brock Chisholm, the WHO’s ﬁrst Director-General, is quoted from
something he wrote in 1951:
Too often countries requesting assistance have been the object of well-meaning
but disastrous attempts to superimpose on the local culture foreign patterns
which, lacking the necessary foundations, are bound to result in friction,
misunderstanding and ultimate failure. In health work, as in all other ﬁelds of
technical assistance, there can be no question of simply transplanting
techniques from one place to another.
Yet transplanting techniques is, of course, what the new agenda for mass
drug administration to control NTDs is about. Indeed, the 2010 WHO report is
all about doing it. Our research ﬁndings, while by no means all negative,
indicate that Chisholm’s warnings remain highly relevant.
Misleading and partial monitoring and evaluation
In February 2010 an editorial appeared in a well known medical journal:
The results of this evaluation do not match with the extravagant claims . . .
made about the programme . . . Evaluation must now become the top priority in
global health . . . complacency is damaging the global health movement.
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Without proper monitoring and accountability, countries and donors—and
taxpayers—have no idea whether or how their investments are working. A lack
of knowledge about whether aid works undermines everyone’s conﬁdence in
global health initiatives, and threatens the great progress so far made in
mobilizing resources and political will for health programmes in low-income
and middle-income countries . . . Evaluation matters . . . It’s time that the global
health community embraced rather than evaded this message.24
These excoriating points in the Lancet were directed at UNICEF, in relation to
the agency’s accelerated Child Survival and Development programme. But
identical observations might soon have to be made about the current target-
obsessed approach to drug distribution for NTD control. Monitoring and
evaluation are systematically inadequate. In large part this is a product of the
perceived need to sustain funding by over-stating achievements. It is
compounded by the competing claims of institutions, including academic
ones, seeking to secure a leading role in what is happening. A consequence is
that the rhetoric of mass drug administration for the control of NTDs is in
danger of moving ever further from the reality, and there will be a backlash.
It is, of course, not the ﬁrst time this has happened. There are striking
similarities with UNICEF’s selective primary health care campaigns in the
1980s, which were shown to have inﬂated coverage data on a large scale. This
perhaps helps explains the irritation in the Lancet’s reaction to UNICEF’s
more recent exaggerations. In recent years somewhat similar concerns have
been raised in detailed studies of immunisation coverage in West Africa,25
and of the control of tuberculosis in Nepal.26 However, it is fair to say that
the problems with respect to rapidly expanding NTD treatment are on a
particularly large scale.
In both Tanzania and Uganda we were surprised by the paucity of
epidemiological data available. For example, information documenting the
prevalence of selected NTDs had been collected at some sites, but not
systematically, or rarely in a manner whereby the results could be drawn
upon to help evaluate the overall eﬀects of treatment with any conﬁdence. In
several instances it was unclear how the sample group had been selected or
why a site or sample population was selected in one year but then ignored in
subsequent years. In other instances data were collected from the same place
over time, but proved diﬃcult to analyse, because there was so much
ﬂuctuation in rates of infection and conjecture as to whether or not mass
treatment had occurred between the collection of samples. We found that it
simply was not a priority to ascertain overall rates of infection or to observe
how these change over time.
To give one example, when we showed results from a report we had located
in Kampala, Uganda to district medical staﬀ in Moyo District, they said they
had never seen them before and were unable to make sense of the data
presented. One senior district oﬃcial explained that we should not draw any
conclusions from the various bits of prevalence data we had uncovered,
because no one knew how they had been collected or how big the sample had
been. He also said that data were being manipulated by politicians, because
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they were making arguments about the number of people resident in the
district for funding purposes. Exactly how this might aﬀect disease
prevalence data was unclear, but it gives a good idea of attitudes. It should
be added that we subsequently carried out a small amount of testing for
schistosomiasis and soil-transmitted helminths in endemic parts of the district
together with some of our medically trained students and the district vector
control oﬃce. It was not particularly diﬃcult to organise, and the vector
control oﬃcer himself was very enthusiastic about doing it with us. It seems
reasonable to ask why it had not been done before on a regular basis.
Equally diﬃcult to interpret are reports documenting the uptake of drugs.
Again, it is often unclear how the summary data have been produced at a
district level, let alone nationally. One striking example were data documenting
the uptake of drugs for the treatment of lymphatic ﬁlariasis and soil-
transmitted helminths in Muhesa district, Tanga region, Tanzania. A report
prepared at district headquarters showed that take up was 100 per cent. We
asked how this was possible, given the guidelines at the time, which speciﬁed
that pregnant women should not be given the drugs. No one was able to give an
explanation of where the 100 per cent rate had come from.
In Tanzania, in particular, we found a persistent practice of increasing
treatment numbers as reporting was passed up though the system. In the
above mentioned example, the records at a more local level had sometimes
been well kept, and corroborated results from our own take-up surveys. Far
from being 100 per cent, actual take up was much lower. At all sites it was
below the 75 per cent target and, at many sites, far below it. At some
locations it was less than 30 per cent (see below for details). Interestingly,
even where the take-up of drugs was found to be good, there was still a
tendency to inﬂate numbers. In Ukerewe Island, for example, the uptake of
drugs among school children for the treatment of S.mansoni and soil-
transmitted helminths ranged from 60 per cent to 78 per cent at the 16
schools studied. Nine of the schools reported these data accurately. The other
seven inﬂated them. Thus, 61 per cent in one case became 96 per cent, and
70 per cent in another became 100 per cent. Even a school that achieved one
of the highest rates of take-up felt the need to increase the reported take-up
of drugs from 79 per cent to 92 per cent.
In Uganda there was less pressure within the national health system to
over-report in this way, although we came across examples of this happening
in Nebbi and Buliisa districts, northwestern Uganda. More of a problem in
Uganda is the fact that good local-level record keeping is much more
unusual, and this has been compounded by the proliferation of drug registers
and changes in the combinations of drugs administered simultaneously. In
the past couple of years the situation has deteriorated, because the USAID-
funded organisation, RTI International, has introduced a new kind of register
for all targeted NTDs. It is meant to replace the previous register documenting
the uptake of drugs for schistosomiasis and soil-transmitted helminiths, as
well as the register documenting the uptake of drugs for onchocerciasis and/
or lymphatic ﬁlariasis. In Moyo district in 2009, for example, numerous
distributors were found to have multiple registers in their possession for
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diﬀerent combinations of NTDs, as well as the new USAID/RTI registers. They
had, unsurprisingly, become confused as to when to use which register. A few
of the most conscientious were found to have abandoned the eﬀort to use any
of them properly, and to be keeping records informally in their own
notebooks. Others were trying to ﬁll in three sets of registers simultaneously
and many others had given up altogether. It had become too complicated and
time-consuming to be worth the trouble. In short, the eﬀect of the USAID/
RTI scale-up has been to undermine the already weak local reporting
mechanisms.
As a consequence, aggregate data on drug uptake in Uganda were found to
be more obviously ‘estimated’ or based on information about the total
number of drugs received and distributed at a district level rather than
grounded in a detailed reporting of actual take-up or observed consumption.
All of this is well known to Ministry of Health staﬀ working on the ground,
but such weaknesses in the data rarely ﬁnd their way into reports or
published articles. Indeed, published epidemiological and parasitological
research on Uganda overwhelmingly suggests that mass treatment can be
shown to have successfully reduced the prevalence and intensity of infection,
as well as clinical indicators of morbidity. Uganda is particularly revealing
about overall trends in assessment of control of NTDs in that it was the ﬁrst
sub-Saharan African country to adopt integrated drug distribution
procedures (launched in 2003 for schistosomiasis and soil-transmitted
helminths, and integrated with other NTDs in 2007).
Much of the published research on the country focuses on children,
reﬂecting the programme’s emphasis on treatment in the schools of targeted
areas. However, even with respect to data on children, there are limitations
with the kinds of studies that have been carried out. This may be illustrated
with reference to research monitoring the impact of annual mass drug
administration on child morbidity.
Cohort studies have re-tested selected school children six months after
each annual round of treatment. If they were found to be positive, they
were re-treated. The results showed declining rates of infection and intensity
of infection (ie worm burden) among those studied.27 However, it cannot be
assumed that these children are representative of all children at the schools
they were attending—not least because they were being given the
opportunity to be treated twice a year instead of once a year. A further
limitation with cohort studies is that they are inevitably biased towards
children of long-term and stable residency. Unfortunately, large numbers of
children in northwestern Uganda do not experience such stability. This fact
explains the high drop-out rates and the eventual abandoning of the
research project.
Problems with the generalisabilty of ﬁndings apply equally to other
methods that have been adopted, such as cross-sectional mapping using the
LOT Quality Assurance sampling method. Twenty-four schools were sampled
in each study district and 15 children were tested in each school. The results
were then mapped using GPS readings for each school.28 Although the results
are visually impressive, the lead researcher himself would not claim that such
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small and restricted sample groups can be reliably used for an overall
assessment of changing patterns of infection following mass treatment. The
research was intended to be indicative, and the claim on one NTD website that
the results show that there is a ‘realistic chance of bringing bilharzia infection
in Uganda to below an intensity level at which it is a major public health
problem’ cannot be sustained.29 Indeed, doubts about such a claim
were underlined by subsequent parasitological testing carried out by Ministry
of Health staﬀ at a small sample of schools in Nebbi district. This was one of
the districts surveyed in the study. Results revealed that many school children
were still infected. At one school, 84 per cent of those tested were reported to
be positive for S.mansoni in 2008.
In addition to epidemiological and geographical surveillance data
exploring the impact of mass drug administration on schoolchildren in
Uganda, endeavours have been made to monitor social responses to mass
drug administration in addition to our own. These have largely focussed on
adults, whose attitudes are key to the long-term viability of the approach.
For example, a ‘process evaluation’ of schistosomiasis control in Uganda,
written by the team implementing the drug distribution, concluded that mass
treatment had been delivered eﬀectively, that it was perceived as beneﬁcial
and that ‘end-users’ are appreciative.30 These ﬁndings build on an as-
sessment undertaken by Lubanga.31 They are based on qualitative data
collected in two districts in Uganda: one on the border with Congo and the
other on the border with Kenya. A series of quotes from study participants in
these two districts are analysed with reference to data documenting the
number of drugs distributed from the Ministry of Health’s headquarters in
Kampala. No attention is paid to the diﬀering political, economic or social
contexts in which participants lived and how this may have inﬂuenced their
perceptions of mass drug administration. It would also have been helpful if
the paper had discussed how the drugs were distributed within and between
districts; whether people actually swallowed them once they arrived in their
villages; and how reported ﬁndings related to data documenting the uptake
of drugs in Ministry of Health registers.
However, limitations in the work cited above are relatively minor
compared to USAID-funded assessments by RTI International. Information
from this source suggests impressive levels of NTD treatment coverage across
the whole county. A map shown on the RTI website illustrates the hugely
successful programme, with links being provided to reports describing how
‘community volunteers make a diﬀerence’ and how ‘the NTD control program
treats war-torn northern Uganda’. Precisely how the data were collected is
not made clear, but from our own observations and discussions with staﬀ in
the ﬁeld, they appear to be based on short questionnaires carried out on a
small number of people in each district. There is no indication to suggest that
any eﬀort was made to look beneath the surface and to see how stated
practice relates to actual behaviour.
Overall, assessments of mass drug administration for NTDs in Uganda raise
more questions than they answer. Unanswered questions include the
following: what proportion of children living in endemic areas attend
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school? What proportion of children who do not attend school or do not
attend on a regular basis receive drugs from community drug distributors?
What proportion of adults receive drugs from mass drug administration on
an annual basis? How are these free drugs perceived by adults and by
children? Are they being swallowed? Do local understandings of the aetiology
and treatment of ‘NTDs’ inﬂuence the consumption of drugs? Are there any
indications to suggest that adults are becoming aware of the beneﬁts of
treatment? Are they beginning to demand that they and their children are
treated on a regular basis? What are the consequences of institutionalising
integrated vertical delivery systems for NTD drug distribution that are
eﬀectively discrete from other work carried out by ministries of health? Is
there any possibility of treatment for NTDs being incorporated into
sustainable national health care systems without continuous, long-term,
international donor-driven support?
Selected ﬁndings from Tanzania and Uganda
Between 2005 and 2009 we carried out ﬁeld research on NTD control at a wide
range of study sites spread across Uganda and Tanzania. We were interested
in the practical ways in which mass drug administration occurred and paid
particular attention to ﬁnding out what actually happened on the ground.
The villages selected for study were located in Nebbi, Buliisa, Moyo and
Adjumani districts, northwestern Uganda, and Busia and Bugiri districts in
southeastern Uganda. The selected districts in Tanzania were Pangani and
Muhesa districts in Tanga region, various locations in Morogoro region, and
Ukerewe Island in Mwanza region.
Research sites were selected on the basis that the prevalence of NTDs was
high among school children and adults for two or more of these diseases or
disease groups. In Uganda the primary focus at all research sites was
S.mansoni and soil-transmitted helminths. This was also the case in Ukerewe
Island, Tanzania. In Muhesa and Pangani districts, Tanga Region, Tanzania,
research initially focused on S.haematobium and soil-transmitted helminths,
but later involved assessing treatment programmes for lymphatic ﬁlariasis as
the drug, albendazole, was used for this disease as well as the treatment of
soil-transmitted helminths. Of all the neglected tropical diseases endemic in
the region, it was also the disease that concerned residents the most.
All sites involved the analysis of Ministry of Health registers documenting
the uptake of drugs for the treatment of S.mansoni, soil-transmitted
helminths and lymphatic ﬁlariasis among school children and adults. In
addition, open-ended, unstructured interviews were undertaken with political
ﬁgureheads, religious leaders, local healers, farmers and ﬁsherman; and
participant observation was carried out (including the observation of what
actually happened when free drugs were distributed at schools and villages).
The generalisability of ideas emerging from this open and exploratory
approach was gauged by undertaking semi-structured interviews with a
minimum of 10 per cent of households at selected villages. To date more than
2000 semi-structured interviews have been undertaken.
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Below we summarise ﬁndings from our research sites, focusing on local
attitudes to being on the receiving end of the campaign and whether or not
people have actually taken treatment. We do not attempt to answer all the
various questions raised at the end of the last subsection, and we do not
provide a detailed overview of our own results—those are presented
elsewhere.32 Our aim is to give an indication of how and why responses to
NTD treatment vary within and between research sites; to highlight the
ramiﬁcations of paying insuﬃcient attention to communication with target
populations, and to illustrate the realities of mass drug administration with
information on actual take-up rates of the distributed tablets.
NTDs are experienced in diverse ways
Diseases falling within the term ‘NTD’ are very diﬀerent from each other—
biomedically and in terms of their perception among target populations. This
profoundly aﬀects local responses, as the following ﬁndings illustrate. They
relate to the three NTDs most common at our research sites: schistosomiasis,
soil-transmitted helminths and lymphatic ﬁlariasis. These are discussed
in turn.
Schistosomiasis. Schistosomiasis, otherwise known as bilharzia, is the broad
descriptive term given to a group of parasitic infections caused by trematode
ﬂatworms of the genus Schistosoma. The majority of human infections in
sub-Saharan Africa are caused by two species of schistosome: S.mansoni and
S.haematobium. These schistosomes have similar lifecycles involving an
aquatic snail intermediate host, the human deﬁnitive host and their mutual
presence in a common environment where transmission occurs: typically
irrigated ﬁelds, irrigation and drainage channels, rivers, ponds and ditches.
The signs and symptoms of S.haematobium and S.mansoni vary. Blood in
the urine (macroscopic haematuria) is the most commonly reported symptom
of S.haematobium, especially among children. In more advanced cases it may
cause damage to the kidneys, urinary tract ﬁbrosis and bladder cancer.
Women may also present with genital lesions, vaginal bleeding and nodules
in the vulva; and men can suﬀer damage to the seminal vesicles and prostate.
It is not unusual, however, for children and adults to be infected with
S.haematobium for many years, and to remain asymptomatic. Similarly,
infection with S.mansoni does not necessarily generate obvious signs and
symptoms. Over time it can lead to gross swelling of the spleen and liver,
blood in the stool, diarrhoea and, in extreme cases, the vomiting of blood.
However, this can take years, even decades, to develop and it does not
happen in all cases. Indeed, there is some conjecture as to how debilitating
infection with S.mansoni or S.haematobium actually is for the majority of
people infected.33
S.mansoni was endemic at all study sites in Uganda as well as on Ukerewe
Island, Tanzania, whereas S.haematobium was endemic in Pangani and
Muhesa districts, Tanzania. With very few exceptions, those interviewed were
unaware of clinical distinctions between these two species. From a public
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health perspective this mattered much more at some sites (notably Nebbi
district, Uganda and Ukerewe Island, Tanzania) than at others (notably
Pangani and Muhesa districts, Tanzania).
To start with Pangani and Muhesa districts: the Swahili term for
schistosomiasis, kichocho, is widely known and local understandings of
kichocho overlap, rather than mirror, biomedical understandings of
S.haematobium. The main sign of kichocho is ‘red urine’ or ‘blood in the
urine’. It is widely understood as an aﬄiction of childhood. This is because
infected children typically present with ‘red urine’ or ‘blood in the urine’ (ie
macroscopic haematuria) whereas adults, who may have acquired their
infection in childhood, typically lose this sign of infection and present with
other signs instead.
The presentation of symptoms inﬂuences perceived aetiology and
responses to treatment. Among children infection is thought to be acquired
while swimming and occurs through their sexual organs or anus. Adults do
not swim and rarely present with ‘red urine’ or ‘blood in the urine’. Not
surprisingly, then, they are not thought to suﬀer from kichocho in large
numbers. The concentration of control programmes in schools conﬁrms these
local perceptions.
There is widespread support for the mass distribution of drugs in schools
for the treatment of kichocho in this part of Tanzania. This, in part, can be
attributed to the fact that local understandings of kichocho overlap with
biomedical understandings of S.haematobium, at least for children. Parents
and teachers alike observed that children suﬀering from kichocho lose the
visible signs of infection, ‘red urine’, when swallowing the tablets. It works.
However, adults in both districts stated that, if mass treatment occurred in
‘the community’, rather than schools, they would be reluctant to swallow the
drugs. As far as they are concerned, kichocho is not a signiﬁcant health issue
for adults.
The situation is much more complicated in places where the mass
distribution of drugs is for the treatment of S.mansoni. In Uganda, for
example, the term ‘bilharzia’ is widely used to describe both S.mansoni and
S.haematobium, although there are very few places where S.haematobium is
found. In common with northern coastal Tanzania, local understandings of
bilharzia diﬀer in important ways from biomedical understandings of either
S.mansoni or S.haematobium and the diﬀerences profoundly aﬀect responses
to the mass distribution of drugs in schools and communities.
By way of illustration, bilharzia is understood as a type of okudi in
Panyimur, northwestern Uganda. Okudi is a general word for worms. Other
types of okudi include okudi ascaris, okudi hookworm and okudi amoeba.
Okudi bilharzia is frequently said to be the type of worm most likely to cause
illness and one informant referred to it as ‘the chairman of worms’. Local
understandings of the signs of okudi bilharzia include an extended stomach,
diarrhoea, bloody diarrhoea and vomiting blood. Biomedical signs of
infection with S.mansoni are similar in a number of important respects, but
this counts for little at a local level, as understandings of aetiology and
eﬀective treatment are so diﬀerent. With respect to aetiology, a diverse array
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of ideas circulates about the aetiology of okudi bilharzia. These include
drinking dirty water, treading on faeces, not washing hands before eating and
swimming in contaminated water. Local informants, including those
associated with the delivery of biomedical health care, were rarely able to
describe the lifecycle of S.mansoni with any accuracy, a fact that can be
attributed to poorly designed health education materials. A Ugandan
primary school textbook, for example, describes the signs and symptoms of
S.haematobium, but does not mention S.mansoni; and thus conveys the
impression that a key sign of infection with bilharzia is red urine. It does not
mention that it is possible to be infected for many years and to remain
asymptomatic. In addition, several booklets and posters depict the lifecycle
of the worm in such a way as to suggest that it possible to see the worms
which penetrate the soft part of the skin in water with the naked eye. This, in
turn, generates comments like ‘we don’t have worms like that!’.
It is equally important to note that the signs of infection associated with
okudi bilharzia can also be interpreted as signs of witchcraft or a local ailment
known as awola. Inﬂicted on an individual by a witch as a result of envy,
awola can only be treated by a kind of witchdoctor known as an ajoga. A
symptom of this ailment is vomiting blood. The same symptom, along with
ascites, is a biomedical indicator of liver damage, a serious and often fatal
complication associated with S.mansoni. However, treatment with biomedi-
cal drugs is deemed dangerous as they are perceived to exacerbate the
condition and, in some circumstances, cause death.
Praziquantel is the drug being distributed for the treatment of S.mansoni. It
is large, strong smelling and has an unpleasant taste. Individuals heavily
infected with S.mansoni often experience side-eﬀects such as diarrhoea and
vomiting after treatment. In many cases this was reported to last for several
days and even weeks. Empirical observations of the impact of treatment, in
combination with divergent understandings of aetiology and treatment, have
led to widespread questioning of the rationale for mass drug administration.
Frequently articulated concerns included the following: ‘why should I take
these drugs? They will make me sick’; others expressed a fear that treatment
with praziquantel (usually referred to as ‘Bayer’) would not only lead to sick-
ness, but also to infertility, miscarriage and even death. In 2005 these concerns
contributed in signiﬁcant ways to the reluctance to swallow drugs in Panyimur.
They were still relevant in subsequent years, but some fears diminished as
empirical observations were being made that people were taking the tablets
without suﬀering long-term, damaging consequences to their health.
Lymphatic ﬁlariasis. Somewhat similar issues arise with lymphatic ﬁlariasis,
which is more popularly known as elephantiasis. It is caused by three species
of mosquito-borne ﬁlarial worms: Wuchereria bancrofti, Brugia malayi and
Brugia timori. In common with schistosomiasis, it is possible to be infected
but free from visible signs and symptoms of infection for many years and to
feel well. Over time and repeated bouts of infection, signs and symptoms
emerge. These typically include the gross swelling of limbs and genital disease
such as hydrocele.
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In Pangani and Muhesa districts, Tanzania local understandings of the
aetiology of lymphatic ﬁlariasis, as well as appropriate responses to the signs
and symptoms of infection, diﬀered considerably from biomedical ap-
proaches. First and foremost, there is no Swahili word for lymphatic
ﬁlariasis. While two of the major biomedical signs of infection, enlarged
testicles and swollen limbs, are locally recognised ‘diseases’, they are
perceived to have separate aetiologies. The disease ‘mabusha’, refers to
enlarged testicles and the disease ‘matende’ refers to swollen limbs. In the
words of a mganga (healer) from Pangani: ‘‘Some people have both mabusha
and matende . . . but they don’t come simultaneously. The fact that mabusha
can be operated on and matende cannot be operated on proves that they are
diﬀerent diseases.’’
The majority of people (including health care workers at government
dispensaries and health centres) draw upon a pluralistic approach to diagnosis
and treatment. As a result, they do not attribute a single cause to either
mabusha or matende. Instead, several causes are likely to be mentioned, with
each cause being accorded equal weight.Mabusha, for example, was typically
attributed to at least one of the following: sex, witchcraft, hernia, diet and
sickness sent by God; the vast majority of people were unaware that it was
caused by infection from the bite of mosquitoes. By contrast, matende was
usually attributed to inherited characteristics and/or witchcraft, a kind of
fever known as mgonzo and, sometimes, the bite of a mosquito.
Perceived aetiology for these two ‘diseases’ not only inﬂuenced the type of
treatment subsequently sought, but also responses to mass treatment. With
respect to mabusha and matende, it was also widely noted that there was no
observable connection between swallowing the drugs (albendazole and
ivermectin) and the alleviation of symptoms. The symptoms did not diminish
in size and the drugs did not, therefore, appear to have an impact. This is
because treatment had not occurred in time to prevent irreversible damage. It
was additionally noted that many people who were being asked to take the
drugs had no symptoms and felt quite well. For these adults, the programme
remained, at best, a mystery. Others were angry and suspicious. The
treatment programme fed into wider concerns about the unspoken agenda of
the government and international aid agencies: Why did the government not
assist with the bigger problems of HIV/AIDS and malaria? Was this just
another endeavour to reduce the birth rate? Were the rural poor being
experimented on with drugs that had not been properly tested?
Soil-transmitted helminths. Soil-transmitted helminths are sometimes re-
ferred to as intestinal worms. From a public health perspective there are three
species that are particularly important: Ascaris lumbricoides (roundworm),
Ancylostoma duodenale (hookworm) and Trichuris trichua (whipworm). All
three species thrive in areas where there is no sanitation system, as the soil
and water can easily become contaminated with faeces containing worm eggs.
Humans are infected by ingesting these eggs (typically from uncooked or
partially cooked food, water or placing unwashed hands into the mouth). In
the case of hookworm, it is also possible for the larvae to penetrate the skin.
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That is, eggs hatch into larvae and rest in the soil. If a person walks barefoot
on the contaminated soil, the larvae can penetrate the skin. There is no direct
person-to-person transmission from fresh faeces as eggs passed in the faeces
need three weeks in the soil before they become infectious. Many people
infected with soil-transmitted helminths experience one or more of the
following symptoms: nausea, abdominal pain and loss of appetite. All three
species are also associated with anaemia and vitamin A deﬁciency.
Local perceptions of soil-transmitted helminths in Tanzania and Uganda
were diﬀerent from biomedical understandings in a number of important
respects. In Pangani and Muhesa districts, Tanzania, for example, soil-
transmitted helminths are referred to as minyoo. They are not associated with
particular signs or symptoms of infection and they are not thought to present
a major health problem. With the exception of hookworm, which is often
referred to as safura, very few people (less than one per cent) had any idea
that there were diﬀerent types of worms with diﬀerent aetiologies. There was,
however, widespread local awareness of minyoo and recognition that taking a
tablet can be curative—not least because those infected could sometimes see
the worms in their faeces.
The drug albendazole is used at all sites in Uganda and Tanzania to treat
soil-transmitted helminths. When oﬀered in isolation, it did not present any
particular problems or concerns to children or adults and was not perceived
to cause serious side-eﬀects. However, there has been a decline in the uptake
of albendazole among both adults and children at most of the sites in which
we have worked, often dropping far below target rates of take-up. This has
been a consequence of the NTD control integration procedures, which have
often meant providing albendazole together with less widely accepted
medicines. A vivid illustration of this point is the fact that, among the Alur
in Nebbi district, the drug for bilharzia is known by the name of Bayer
(rather than praziquantel) and the drug albendazole is known as ‘anti’ or the
‘escort’. In other words, it is perceived as an antidote to what were locally
thought to be serious side-eﬀects associated with the drug praziquantel. In
parts of Tanzania dramatic declines in albendozole take-up were also noted,
especially in locations where it was provided together with ivermectin for the
treatment of lymphatic ﬁlariasis.
Declines in albendozole take-up were found to be less steep in schools,
because children were more likely to take combinations of NTD drugs if
instructed to do so by their teacher. However, health education materials
used at the time of treatment tended to be confusing. Children were often
informed about soil-transmitted helminths, but not about other diseases,
making it hard for them—or their parents—to understand why there were
given other drugs too. At sites in coastal Tanzania, for example, Swahili
language pamphlets were given out explaining soil-transmitted helminths at
the time that school treatment for schistosomiasis was occurring in 2007.
On that occasion albendozole was not being distributed, because the
children were supposed to have received it as part of an earlier distribution
of treatment for lymphatic ﬁlariasis. Most teachers were found to be
unaware that this was the case and could not explain what the drugs they
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were giving out were meant to treat. At a village level no one interviewed
knew that albendazole had the multi-purpose of treating minyoo, mabusha
and matende.
Inadequate communication and outreach
The distribution of NTD drugs in Uganda and Tanzania was organised in
similar ways. Drugs were sent from Kampala and Dar es Salaam to local
headquarters (directly to districts in Uganda; to regions and then districts in
Tanzania). District vector control oﬃcers distributed drugs to primary
schools and health centres and, after attending a training session, teachers,
volunteer drug distributors and sometimes health workers took on the task of
distributing drugs within villages and schools. It sounds relatively
straightforward and, at least with respect to treatment programmes in
schools, it has often been possible to ensure that the majority of children
registered at school and attending on the days of distribution receive free
drugs, partly because, as has been noted, they will do what their teachers tell
them to do. In these school contexts the actual swallowing of drugs is usually
observed by the distributors. However, drug distribution in schools is by no
means always so straightforward, and away from school environments
serious diﬃculties are quite common.
In large part this can be attributed to insuﬃcient and inappropriate
‘sensitisation’ and ‘mobilisation’. The type of information conveyed along-
side the distribution of drugs is little more than information about how and
when to take them. It does not challenge or engage with pluralistic outlooks
and ways of thinking, and makes little attempt to explain the aetiology of the
diseases being treated, how it is possible to be asymptomatic, how the
medicines provided work, and why mass treatment is provided without
diagnostic procedures. Various posters are sometimes displayed and
occasionally pamphlets are distributed, but these are generally of a poor
quality, often confusing or even wrong. One example has already been
mentioned: misleading pictures illustrating the lifecycle of schistosomiasis.
Another example is the use of photographs in the new NTD integrated
treatment registers being distributed in Uganda. These purportedly show
symptoms of onchocerciasis. In fact, they depict symptoms of lymphatic
ﬁlariasis. In short, lip service is paid to the importance of health education
but the reality is that communication with target populations is not
prioritised, is mostly superﬁcial, and can be experienced as patronising.
Indeed, the use of overly-simplistic messages comes close to being a deliberate
policy, justiﬁed on the grounds that to explain things properly would be too
complex for health educators and the target audience.34
Not surprisingly, then, responses to these vertical, biomedical programmes
remain bound within existing systems that attribute locally understood
aﬄictions such as awola, mabusha and matende to very diﬀerent aetiologies,
treatments and preventive actions. We have also found that, whenever we
have held public meetings to discuss the drug distributions, there is usually a
barrage of intelligent questions posed by those being oﬀered them. Among
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the most frequently posed are versions of the following: ‘why should we take
the tablets if we are going to go back in the water, because we will be
reinfected?’ and ‘we have been told not to take medicines unless we are
properly diagnosed, so why are you telling us to take treatment when we may
not have anything wrong with us?’
On occasion the lack of adequate communication about the rationale for
mass treatment for biomedically deﬁned tropical diseases that are not
necessarily recognised at a local level has fuelled conspiracy theories and
collective resistance. This can range from being absent on distribution days to
violent protests. The latter have occurred where school distributions have
been particularly poorly handled and where there is local suspicion of the
motives of central government or district of authorities. In many respects it is
surprising that it has not occurred more often than it has.
Imagine a situation in the UK whereby a healthy child goes to school in the
morning, but comes home in the afternoon with stomach pains, vomiting
and/or diarrhoea. The child then tells her mother and father that her teachers
made her swallow several large tablets and this had been something to do
with treatment for invisible worms. The parents not only discover that their
child is not making this up, but they also ﬁnd out that several of the child’s
friends have become ill with similar symptoms. Almost certainly there would
be protests and the school staﬀ would be held to account. This imaginary
scenario gives an idea of how mass drug administration to school–aged
children in Africa can be experienced the ﬁrst time it is attempted.
Where there have been several drug distributions, the chances of signiﬁcant
side-eﬀects seem to lessen. This has not been studied systematically but it is
probably because the intensity of infection and infection rates have declined
with previous treatments. Where this is reported, repeated treatment in schools
shows signs of becoming routine. In some research sites, such as in Adjumani
District in Uganda, we found that school children had gained a reasonable
level of understanding about the control of the diseases being treated. In fact,
they often had more precise knowledge about some diseases than community
drug distributors or their parents. At other locations in Uganda and Tanzania,
however, people became so angry about what was happening that distribution
had to be stopped. In both countries there were conspiracy theories that kept
circulating about what the drugs were really for, especially in locations in
which people feel politically marginal—such as parts of northern Uganda,
northern coastal Tanzania and parts of Morogoro.
In Tanzania matters came to a head in places around Morogoro in 2008.
Distribution in schools of tablets for schistosomiasis and soil-transmitted
helminths provoked riots, which had to be contained by armed police. It
became a signiﬁcant national incident, and one of the consequences has been
the delay in Tanzania adopting a fully integrated NTD programme, and the
scaling back some existing drug distributions. The riots were by far the most
extreme example of resistance to NTD drug distributions, but the sentiments
expressed by the protesting mob were far from unique. Drawing on research
at all our research sites, a summary of some of our key ﬁndings on the take-
up of drugs is presented below.
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Realities of drug take up
In northwestern Uganda we found that the take up of drugs for S.mansoni
and soil-transmitted helminths was very variable in locations in Nebbi
Distrct. To be more speciﬁc: in 2004 the average self-reported uptake of
drugs among adults ranged from 62 per cent to 78 per cent in the three
parishes that constitute Panyimur sub-county. In 2005 uptake ranged from
32 per cent to 43 per cent in these three parishes; and in 2007 it ranged from
33 per cent to 59 per cent.35
Across Lake Albert in Buliisa District rates were also variable, with the
average uptake of drugs among adults for schistosomiasis and soil-
transmitted helminths ranging from eight per cent to 27 per cent in 2005,
four per cent to 15 per cent in 2006; 36 per cent to 58 per cent in 2007 and
46 per cent to 91 per cent in 2008. In villages where the uptake of drugs was
low, this could be attributed to a combination of supply problems and local
antipathies between resident ethnic groups.
Further north, along the Nile close to the Sudan border, the uptake of
drugs among adults in Adjumani and Moyo districts was variable again.
This was partly the result of a policy of selective treatment in some years,
whereby adults were only encouraged to take the drugs if they thought they
might be infected. On the other hand, very high take-up rates occurred at
some locations when there was distribution of food relief at the same time
as tablet distribution. In Moyo district self-reported survey data from seven
villages suggested an average uptake of 39 per cent, 41 per cent and
55 per cent in 2006, 2007 and 2008, respectively. In neighbouring Adjumani
district self-reported uptake of drugs for S.mansoni and soil-transmitted
helminths among adults at seven selected sites averaged 29 per cent,
60 per cent, 51 per cent and 74 per cent in 2005, 2006, 2007 and 2008,
respectively. Rates of take-up recorded at primary schools tended to mirror
adult take-up, especially in Adjumani district. They reached very high levels
on occasions that food was provided to the children at school on
distribution days, but were found to drop precipitously when food relief
was withdrawn.
At the other end of the country in Busia District, located in the southeast
near the Kenyan border, average rates of take-up among adults at selected
sites were 67 per cent in 2008 and 64 per cent in 2009. In neighbouring Bugiri
district, however, average uptake was 43 per cent in 2007 and 34 per cent in
2008. Mass drug administration did not occur in 2009 as the vector control
oﬃcer was seriously ill. In the light of information available, it seems likely
that the relatively successful ﬁgures in Busia district can be attributed to a
political agenda of making Busia into a ﬂagship district, partly because a
large ﬁsh processing plant had been built there. A policy had been introduced
to drastically reduce the number of people involved in ﬁshing related
activities, and to closely regulate access to the shore of Lake Victoria. Many
people were displaced into neighbouring Bugiri district (which includes
islands in the lake), leaving the relatively wealthy and well-connected to
receive NTD treatment. Not surprisingly there are indications that rates of
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schistosomiasis infection in Busia have declined, but the limited evidence
available suggests that there are high rates in Bugiri.
Moving to Tanzania, we found that the uptake of drugs among adults for
S.mansoni and soil-transmitted helminths in Ukerewe Island ranged from
18 per cent to 74 per cent at 14 selected villages in 2007, with an overall average
of 44 per cent. As noted previously, the uptake of drugswasmuch higher among
school children and sometimes exceeded the target of 75 per cent coverage.
In areas of Tanga region we found wide ﬂuctuations in the uptake of drugs
for schistosomiasis, as well as for soil-transmitted helminthiases and
lymphatic ﬁlariasis. S.haematobium is endemic in this part of Tanzania.
Parents were found to be positive about their children being treated at
school, with recorded uptake often exceeding the target coverage of
75 per cent. However, the uptake of drugs for the treatment of lymphatic
ﬁlariasis and soil-transmitted helminthiases was low. In Mwembeni village,
Pangani district, for example, self-reported uptake of drugs among adults fell
from 70 per cent in 2004 to 49 per cent in 2006 and 36 per cent in 2007. In
neighbouring Jaira village uptake fell from 57 per cent in 2004 to 49 per cent
in 2006 and 40 per cent in 2007. Similar trends were observed in coastal parts
of Muhesa district. In Kigombe East and Kigombe West, for example,
uptake fell from 63 per cent and 44 per cent, respectively in 2004 to
27 per cent and 34 per cent in 2006 and 27 per cent and 26 per cent in 2007.
Interestingly, closer to Muhesa town, uptake rose from 47 per cent and
40 per cent in 2004 in Bwembwera and Magila, respectively to 68 per cent
and 43 per cent in 2006 and 65 per cent and 70 per cent in 2007.
In Doma village, Morogoro, Ministry of Health registers documenting the
uptake of drugs for the treatment of onchocerciasis suggested that uptake fell
from 31 per cent in 2004 to 29 per cent in 2006 and 17 per cent in 2007.36 This
was a location of considerable antipathy to the NTD distributions, and was
the site of some of the worst riots in 2008 when attempts were made to treat
schistosomiasis in schools.
Overall our research reveals that claims about the eﬀective delivery of drugs
and positive responses tomass treatment by end users in Uganda and Tanzania
are not borne out by the evidence. However, there is an eagerness to take the
drugs in some locations, and in northern Uganda we found that the majority of
people of long-term residence in areas endemic for S.mansoni had taken
praziquantel at least once. This appeared to be conﬁrmed by testing we carried
out ourselves with district health staﬀ and some of our students in Moyo and
Nebbi districts, as we found generally low rates of infection among stable
residents, even among resident ﬁsherfolk living on the Nile. This contrasted
dramatically with very high rates among recent migrants, which doubtless
helps explain the very high recorded rates of infection—or re-infection—
among school children in Nebbi mentioned above (more than 80 per cent at
one school tested). Children swim in Lake Albert, where short-term migrants
have to defecate because of a lack of pit latrines.
Finally, while we made every eﬀort to triangulate our ﬁndings (by looking
at data documenting the uptake of drugs in ministry of health registers,
discussing a wide range of issues with community drug distributors, teachers,
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other adults and children, and observing drug distribution days), we cannot
be sure that all those we recorded as having taken the drugs actually
consumed them, or that they consumed them in the correct doses. In many
instances, revisiting households and follow-up interviews revealed that
tablets had been ‘taken’ but not swallowed. On numerous occasions we
were shown tablets that were being kept in case someone in the family
became ill. Observations of distributions made it clear, in some locations,
just how hard it was for a drug distributor to insist on watching a recipient
consume the medicines. Some teachers tried to force their pupils to do it,
not always successfully. With adults this was not an option, although, on a
few occasions, informants spontaneously suggested that a degree of force
might be appropriate. As one put it ‘if it was really important to take these
tablets there would be laws to make us’. It was a good point. At only one
of our sites was public health legislation used systematically, and that was
in Busia, where it was evoked to remove people from the vicinity of Lake
Victoria.
Conclusion
There is no question that a focus on the parasites of the poor is appropriate.
Anyone who has seen the eﬀects of long-term infection on those suﬀering
from these NTDs would ﬁnd it hard to deny that treatment should be
provided; and the oﬀer of very cheap or free medicines from the major drug
companies is very welcome. There is a remarkable opportunity to make a real
diﬀerence to large numbers of deprived people. However, it is also hard not
to be exasperated by the grandstanding rhetoric and exaggerated claims of
some protagonists. The targets associated with the MDGs have not helped in
this respect, and there is a real possibility that purported achievements will
become more and more illusory.
The priorities of institutions competing to secure and sustain funding
already seem to be more important than sober assessments of what is
happening on the ground. As mass drug administration scales up, it becomes
ever harder to learn from what has worked and what is failing. This can only
be counterproductive. Thus, while the 2010 WHO report on NTDs is a positive
initiative, it is a bit disappointing, not least because it uncritically accepts
summative data reporting high rates of drug uptake. Parts of the report read
like an elaborate application for funding—particularly those sections
asserting the WHO’s pivotal co-ordination role with reference to some
creative historicising. Would it not be better to set out an agenda for more
rigorous research and monitoring?
Everyone we have spoken to inside the drug distribution programmes is
well aware that not all of what is claimed is in fact true. But they feel
compelled to sweep ongoing problems under the carpet for fear that reso-
urces will be withdrawn.37 People living in places like the Gezira/Managil
irrigation scheme in Sudan, where mass drug administration has occurred in
the past, are in danger of returning to former levels of infection following the
termination of control projects. So it is understandable that those committed
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to the approach are sensitive to anything that might jeopardise resourcing
and supply. However, a range of problems has arisen with mass drug
administration, and if these problems are ignored, they are likely to
undermine NTD control programmes anyway.
A good example of the setting aside of critical voices is the response to the
concerns raised by Bruno Gryseels. Aware that the reviewing process in
conventional medical journals was likely to be very time consuming and would
probably require him to tone down his views to secure publication, he decided
to write an extended letter to the Financial Times.38 Several of the points we
have discussed here are addressed in the letter, as well as a warning that large
scale, long-term distribution of drugs may trigger drug resistance in recipient
populations. This is a particularly sensitive issue, for obvious reasons. As far as
we know, there are no data indicating that it has happened with medicines used
in NTD control. But it is hardly an unreasonable point to raise, not least because
current methods of monitoring might not pick it up. The response was a
formulaic attack, purportedly penned by leading African supporters of current
roll-out schemes. Rather than addressing the substantive issues raised (other
than to note that drug resistance has not yet been observed), Gryseels was
castigated for raising criticisms on the grounds that ‘his position from an
African perspective is unethical and a violation of the fundamental right to
heath and contrary to the health policy of African countries’.39 Gryseels, it
should be noted, is not an anthropologist like us, whose workmight be set aside
as interesting but ‘anecdotal’. He is head of the Institute of TropicalMedicine in
Antwerp. Perhaps that was the reason for the co-ordinated rebuttal.
Is closing oﬀ debate and discussion in this way ever useful? Are donors and
drug companies really so unwilling to accept that there might be complications
and problems with the philanthropic eﬀorts they support? Surely there is space
to address diﬃculties and disagreements without resorting to blanket denials
and defensive assertions. To repeat the key point in the Lancet editorial cited
above: ‘Without proper monitoring and accountability, countries and
donors—and taxpayers—have no idea whether or how their investments are
working.’40 To prevent that happening, an inﬂuential institution has to be in a
position to lay down guidelines and benchmarks, objectively assess treatment
process, and demonstrate that things are not going according to plan, if that is
indeed the case. Basically it must be in a position to create adequate space for
debate and to learn from what does not work.
It seems that schools of public health are so caught up in a desperate
scramble for grants that they will not be able to do that. Our own research
has been supported by Alan Fenwick’s group based at Imperial College,
partly because Fenwick himself recognises the value of an alternative
perspective to the consensus-driven analysis that surrounds him—and to
which he has himself been such a leading contributor. But his attitude is
relatively rare. More generally assessments of programmes by university-
based medical research centres are vulnerable to being compromised by soft
funding. The situation with subcontracted commercial organisations like RTI
International is worse. They are, after all, openly competing with each other
to provide services. They are structurally connected with temporal
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constraints, pre-deﬁned outcomes, and face continuous pressure to position
themselves to bid for the next aid grant. This does not preclude them from
operating eﬃciently, but they could not survive if they chose to rock the boat.
It is also unlikely that things will change if a new Global Fund for NTDs is
established. Such a fund will channel resources into setting up and sustaining
yet another UN-linked bureaucracy, and will do all it can to redirect
resources from other institutions by arguing that it can reach targets more
quickly. Temptations to exaggerate results will intensify. Do current eﬀorts
by the WHO to gain the initiative in co-ordinating global NTD control,
underlined by its ﬁrst ever major report on the issue, mean that it will
succumb to similar pressures?
Mass drug administration for several debilitating diseases has the potential
to work. We have seen the beneﬁts for impoverished people at some of our
research sites. However, it will not succeed overall and what has been
achieved will not be sustained unless there is a serious eﬀort to assess what is
actually happening on the ground. Practices will need to be adjusted to deal
with the kinds of issues we have highlighted in our research. Setting public
health benchmarks based on robust information is the kind of role that the
WHO was set up to play. It has sometimes found it hard to assert such a
position in the past, such as when it was eﬀectively sidelined by UNICEF in the
1980s or by the World Bank in the 1990s. But someone has to be in able to
say that the emperor has no clothes when that is the case, and hopefully to do
so in time to dress him, before the consequences become too serious.
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